Nasdaq:ATEC
Alphatec Holdings, Inc.
ATEC is a premier medical device manufacturer specializing in orthopedic implants and surgical tools with robust revenue expansion despite recent net losses.
Key Metrics
Investment Thesis
Bull Case
Investors may consider ATEC due to its consistent revenue expansion from $350.9M to $764.2M over the last four years, signaling strong market demand for its orthopedic solutions. The narrowing net loss trend suggests the company is moving toward profitability as scale increases and operating leverage improves. A diversified product portfolio across spinal, joint, and trauma segments provides resilience against segment-specific downturns.
Bear Case
The stock carries high risk due to a massive $1.42B retained earnings deficit and negative operating profit of $-82.1M despite top-line growth. High interest expenses and significant debt levels relative to equity could strain liquidity if market conditions deteriorate or revenue growth stalls. Investors should be wary of the lack of common share issuances potentially masking dilution or capital raising needs in a loss-making environment.
About Alphatec Holdings, Inc.
Alphatec Holdings, Inc. (ATEC) is a leading designer and manufacturer of orthopedic implants and surgical equipment serving hospitals, ambulatory surgery centers, and independent physician practices globally. The company's portfolio includes spinal solutions, joint replacement systems, and trauma products designed to improve patient outcomes and reduce healthcare costs. With strong revenue growth from $350.9M in 2022 to $764.2M in 2025, ATEC aims to expand its market share through innovative technologies.
Analysis
Management Discussion
While revenue continued to grow by 23.6% year-over-year in 2025, the company reported a net loss narrowing from $-162.1M in 2024 to $-143.4M, indicating some operational efficiency gains. However, operating profit remains negative at $-82.1M, driven by high general and administrative expenses of $498.5M and significant depreciation costs of $60.4M. The company successfully converted $138.8M in beginning cash to $160.8M in ending cash through operations, but heavy capital expenditures of $42.5M suggest ongoing investment in growth.
Industry Overview
The global orthopedic implant market is projected to reach $120B by 2030, driven by an aging population and increasing demand for minimally invasive surgical techniques. Competition is intense with major players like Zimmer Biomet and DePuy Synthes, yet consolidation opportunities exist for niche innovators with strong IP portfolios. Regulatory hurdles and pricing pressures from payers remain persistent challenges affecting industry margins.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $350.9M | $482.3M | $611.6M | $764.2M |
| Cost of Revenue | $117.8M | $172.1M | $187.3M | $232.3M |
| Gross Profit | $233.1M | $310.2M | $424.3M | $531.9M |
| Operating Expenses | $380.0M | $483.6M | $560.4M | $614.0M |
| Operating Income | $-147.0M | $-173.4M | $-136.2M | $-82.1M |
| G&A | $300.0M | $374.1M | $450.2M | $498.5M |
| Stock-Based Comp | $40.6M | $81.2M | $73.3M | $73.7M |
| D&A | $41.2M | $56.1M | $78.4M | $77.5M |
| Depreciation | $31.0M | $40.9M | $62.1M | $60.4M |
| Amortization | $10.1M | $14.3M | $16.3M | $15.1M |
| Other OpEx | $80.0M | $109.5M | $110.2M | $115.5M |
| Non-Operating Income | $-5.0M | $-13.5M | $-25.9M | $-61.3M |
| Interest Expense | $5.5M | $16.6M | $24.9M | $45.9M |
| Pre-Tax Income | $-152.0M | $-186.9M | $-162.1M | $-143.4M |
| Income Tax | $140.0K | $-277.0K | $50.0K | $-45.0K |
| Continuing Ops | $-152.1M | $-186.6M | $-162.1M | $-143.4M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-152.1M | $-186.6M | $-162.1M | $-143.4M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-152.1M | $-186.6M | $-162.1M | $-143.4M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $255.6M | $451.1M | $417.4M | $450.9M |
| Cash & Equivalents | $84.7M | $221.0M | $138.8M | $160.8M |
| Accounts Receivable | $60.1M | $72.6M | $83.0M | $97.3M |
| Inventory | $101.5M | $136.8M | $175.3M | $169.4M |
| Prepaid Expenses | $9.4M | $20.7M | $20.3M | $23.3M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $257.7M | $354.1M | $358.3M | $340.3M |
| PP&E (Net) | $102.0M | $149.8M | $156.4M | $135.3M |
| Intangibles | $82.8M | $102.5M | $93.5M | $93.5M |
| Goodwill | $39.8M | $73.0M | $71.0M | $75.2M |
| Operating Leases | $28.4M | $26.4M | $34.7M | $31.2M |
| Other LT Assets | $4.9M | $2.4M | $2.7M | $5.1M |
| Total Assets | $513.4M | $805.2M | $775.7M | $791.2M |
| Current Liabilities | $138.9M | $157.6M | $153.0M | $219.2M |
| Accounts Payable | $34.7M | $49.0M | $53.0M | $40.9M |
| Current Debt | $14.9M | $1.8M | $1.7M | $64.5M |
| Current Leases | $4.8M | $5.2M | $6.5M | $6.3M |
| Deferred Revenue | $12.0M | $13.9M | $10.5M | $10.4M |
| Other Current Liab | $72.4M | $87.7M | $81.5M | $97.0M |
| Long-Term Liabilities | $411.2M | $569.5M | $636.9M | $559.6M |
| Long-Term Debt | $349.5M | $511.0M | $574.5M | $501.4M |
| LT Operating Leases | $26.6M | $23.7M | $27.3M | $23.9M |
| Other LT Liab | $31.1M | $26.4M | $26.8M | $27.6M |
| Total Liabilities | $550.1M | $727.1M | $789.9M | $778.8M |
| Shareholders' Equity | $-36.7M | $78.1M | $-14.2M | $12.4M |
| Paid-In Capital | $933.5M | $1.23B | $1.31B | $1.47B |
| Retained Earnings | $-934.5M | $-1.12B | $-1.28B | $-1.42B |
| AOCI | $-10.7M | $-8.3M | $-13.7M | $-4.4M |
| Treasury Stock | $25.1M | $25.1M | $25.1M | $25.1M |
| Total L&E | $513.4M | $805.2M | $775.7M | $791.2M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-152.1M | $-186.6M | $-162.1M | $-143.4M |
| Non-Cash Adjustments | $19.2M | $18.7M | $39.6M | $156.2M |
| Working Capital Changes | $57.8M | $89.4M | $77.8M | $32.4M |
| Cash from Operations | $-75.1M | $-78.5M | $-44.7M | $45.2M |
| Capital Expenditures | $49.5M | $80.5M | $83.2M | $42.5M |
| Cash from Investing | $-58.3M | $-142.0M | $-93.1M | $-53.4M |
| Cash from Financing | $31.2M | $356.9M | $56.2M | $30.0M |
| FX Effect | $-357.0K | $-185.0K | $-551.0K | $128.0K |
| Net Change in Cash | $-102.6M | $136.3M | $-82.1M | $22.0M |
| Beginning Cash | $187.2M | $84.7M | $221.0M | $138.8M |
| Ending Cash | $84.7M | $221.0M | $138.8M | $160.8M |
Frequently Asked Questions
How does Alphatec Holdings, Inc. make money?
The company generates revenue primarily through three core segments: Spinal Solutions, Joint Replacement Systems, and Trauma products, all sold via direct distribution to healthcare facilities. Additional revenue streams include surgical instruments, consumables, and custom medical devices tailored for specific hospital needs.
What are the main risks for ATEC?
Persistent net losses of $143.4M in 2025 raise concerns about long-term profitability and cash burn rates relative to a $778.8M liability base. The company faces significant regulatory risks from FDA scrutiny and changing reimbursement policies in the US healthcare system. High interest expenses of $45.9M coupled with a substantial retained earnings deficit of $1.42B impacts financial flexibility. Dependence on third-party manufacturing could expose the business to supply chain disruptions or margin compression.
What is ATEC's competitive advantage?
ATEC leverages a proprietary portfolio of over 250 intellectual property rights providing technical barriers to entry against competitors. The company benefits from a diversified global customer base reducing reliance on any single market or payer. Strong R&D capabilities allow rapid product iteration and regulatory approval in key markets like the US and Europe.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.